ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc (ENTA)

7.22
0.04
(0.56%)
Closed March 09 3:00PM
7.22
0.00
(0.00%)
After Hours: 4:17PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
7.22
Bid
5.65
Ask
7.78
Volume
166,264
6.915 Day's Range 7.30
4.71 52 Week Range 17.80
Market Cap
Previous Close
7.18
Open
7.14
Last Trade
22
@
7.22
Last Trade Time
Financial Volume
US$ 1,184,884
VWAP
7.1265
Average Volume (3m)
582,021
Shares Outstanding
21,332,544
Dividend Yield
-
PE Ratio
-1.33
Earnings Per Share (EPS)
-5.44
Revenue
67.64M
Net Profit
-116.05M

About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of... Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Enanta Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ENTA. The last closing price for Enanta Pharmaceuticals was US$7.18. Over the last year, Enanta Pharmaceuticals shares have traded in a share price range of US$ 4.71 to US$ 17.80.

Enanta Pharmaceuticals currently has 21,332,544 shares outstanding. The market capitalization of Enanta Pharmaceuticals is US$153.17 million. Enanta Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.33.

ENTA Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.65-8.259212198227.877.9086.952589357.28633358CS
42.2144.11177644715.018.764.735546597.29776985CS
120.9715.526.258.764.715820216.10720479CS
26-4.34-37.543252595211.5613.36994.713917517.37637977CS
52-8.23-53.268608414215.4517.84.712846319.49599823CS
156-58.99-89.095302824366.2179.4954.7126204423.90902523CS
260-44.49-86.037516921351.711024.7122457833.32557717CS

ENTA - Frequently Asked Questions (FAQ)

What is the current Enanta Pharmaceuticals share price?
The current share price of Enanta Pharmaceuticals is US$ 7.22
How many Enanta Pharmaceuticals shares are in issue?
Enanta Pharmaceuticals has 21,332,544 shares in issue
What is the market cap of Enanta Pharmaceuticals?
The market capitalisation of Enanta Pharmaceuticals is USD 153.17M
What is the 1 year trading range for Enanta Pharmaceuticals share price?
Enanta Pharmaceuticals has traded in the range of US$ 4.71 to US$ 17.80 during the past year
What is the PE ratio of Enanta Pharmaceuticals?
The price to earnings ratio of Enanta Pharmaceuticals is -1.33
What is the cash to sales ratio of Enanta Pharmaceuticals?
The cash to sales ratio of Enanta Pharmaceuticals is 2.28
What is the reporting currency for Enanta Pharmaceuticals?
Enanta Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Enanta Pharmaceuticals?
The latest annual turnover of Enanta Pharmaceuticals is USD 67.64M
What is the latest annual profit for Enanta Pharmaceuticals?
The latest annual profit of Enanta Pharmaceuticals is USD -116.05M
What is the registered address of Enanta Pharmaceuticals?
The registered address for Enanta Pharmaceuticals is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Enanta Pharmaceuticals website address?
The website address for Enanta Pharmaceuticals is www.enanta.com
Which industry sector does Enanta Pharmaceuticals operate in?
Enanta Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.14M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.92M
KZIAKazia Therapeutics Ltd
US$ 1.1899
(40.80%)
4.5M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
577.55k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.59M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.18M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108.27k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
336.99k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
341.94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
143.04M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
142.23M

ENTA Discussion

View Posts
alertmeipp alertmeipp 4 days ago
We will see. Would be a very different company a year out.
👍️0
dewophile dewophile 4 days ago
I don't think they are going to shake up management at least through phase 1 of the kit inhibitor
once they get into POC they are going to want experts in those disease areas, and if RSV is totally partnered out I would think rotate those folks out
👍 2 👍️ 1
alertmeipp alertmeipp 5 days ago
If they partner both then they may as well sell the company

Maybe the plan is to sell it actually, as if the plan is to run the immology further, we should expect a CEO succession plan soon, right?
👍️ 1
dewophile dewophile 5 days ago
I think that is their plan. If they partner both then they may as well sell the company
👍️ 3
go seek go seek 6 days ago
Will there be PR on $30M tax refund?
👍️ 2 😄 1
alertmeipp alertmeipp 6 days ago
I wish ENTA can partner out RSV soon and keep the immology programme in house as long as possible. The upside will be quite unimaginable if they have some success there.
👍️ 2
dewophile dewophile 6 days ago
THRD is looking to partner up* but I’m not sure that is a good proxy for value of the kit drug bc their healthy volunteer data was a bit murky. *they announced a workforce reduction and are exploring “strategic options”
The LFT abnormality in the highest dose arm was of greater magnitude than the 2 placebo elevations. They also had more hematological toxicity than expected, especially at the highest dose level (where they did get to 80 percent reduction in mean tryptase). So they might be more limited in dosing moving forward.

https://ir.thirdharmonicbio.com/static-files/1ef636b6-3f8f-4c48-b0f8-0b4595844526

BPMC had a recent poster with their phase 1 data which seemed cleaner.

https://www.blueprintmedicines.com/wp-content/uploads/2025/03/Blueprint-Medicines-AAAAI-WAO-2025-BLU-808-Wild-Type-KIT-Safety-PK-Healthy-Volunteers-Poster.
👍️0
alertmeipp alertmeipp 6 days ago
Interesting to see addtional partnership around $ENTA's new focus area. One day, it will be with $ENTA I hope.
Or, $PFE just buy us out.
👍 1
dewophile dewophile 6 days ago
I think THRD licensed their drug(s) from NVS so interesting. Maybe they like this MOA better, maybe they regret the decision to outlicense the kit to THRD given the data CLDX has been able to produce, but now that THRD may be dead in the water probably not much sellers remorse there
I would think ENTA's drug is worth a comparable amount or more based on the fact c-kit is more derisked as a target than this (INCY recently had to halt their trials for preclinical tox at the POC stage - they paid 750M less than a year ago for a phase 1 asset for this target)

https://investor.incyte.com/news-releases/news-release-details/incyte-provides-update-early-phase-mrgprx2-and-mrgprx4-programs
👍️ 6
DewDiligence DewDiligence 6 days ago
NVS licenses Kyorin preclinical CSU compound_for $55M up-front and $833M total biobucks:

https://www.kyorin-pharm.co.jp/en/news/docs/KYORIN%20and%20Novartis%20Enter%20into%20a%20Global%20License%20Agreement%20for%20KRP-M223.pdf Under this agreement, KYORIN grants Novartis an exclusive worldwide license to develop, manufacture, and commercialize KRP-M223. KYORIN retains an option to commercialize in Japan and manufacture the product for the Japan market with Novartis retaining an option to co-promote with KYORIN in Japan.

KYORIN will receive an upfront payment of USD 55 million and is eligible to receive milestone payments of up to USD 777.5 million tied to the progress of development, approval, and commercialization of KRP- M223 as well as tiered royalties on net sales.

KRP-M223 is an MRGPRX2 antagonist for allergic and inflammatory diseases involving mast cells, such as chronic spontaneous urticaria. KYORIN has developed KRP-M223 which now is in the pre-clinical stage and Novartis will be responsible for global development. Immunology is a cash machine, evidently. Chronic diseases such as CSU are plainly more lucrative for drugmakers than acute illnesses.
👍️ 5
floblu14 floblu14 6 days ago
O/T - Finally, after many, many years with GTCB, MNTA and now ENTA, I have finally won an OSCAR for best STAMINA & ANIMATED FILM FEATURE:



That's FLO not FLOW! Standing ovation, please.LOL
👍️ 4
biotech_researcher biotech_researcher 1 week ago
There is no such thing as a certainty in this business...
👍️0
alertmeipp alertmeipp 1 week ago
That would make me and my bank account very happy.

I hope you can bank on it soon. 3x overnight is possible if the right deal htis 😀
👍️0
vinmantoo vinmantoo 1 week ago
They'll be fine. Just need to partner up

That would make me and my bank account very happy.
👍️ 2
wags23 wags23 1 week ago
They'll be fine. Just need to partner up
👍️ 2
alertmeipp alertmeipp 1 week ago
Hope they would get some sort of settlement before they exhausted all venue, it’s time to wrap this chapter up.
👍️ 3
DC15 DC15 1 week ago
Maybe Enanta should have sold more stock, CLDX is taking their product through phase 3 and they have a lot of cash. I am not certain why CLDX believes in its product more than Enanta can believe in their RSV, and COVID products. At one time Enanta was touting their PL-pro candidates as pan viral including flu. noro, rhinoviruses, and COVID.

Was that for real, was there an expectation for legitimate success?
👍️0
floblu14 floblu14 1 week ago
Appeal Update - Enanta Pharmaceuticals, Inc. v. Pfizer Inc.

Filing 1 Appeal docketed. Received: 02/04/2025. [1067471] Entry of Appearance is due on 02/20/2025. Certificate of Interest is due on 02/20/2025. Docketing Statement is due on 02/20/2025. Appellant's brief is due on 04/07/2025. [IMH] [Entered: 02/06/2025 03:26 PM]

https://dockets.justia.com/docket/circuit-courts/cafc/25-1427

By June (?) we might have a decision.
👍️ 7
dewophile dewophile 1 week ago
Well the first DDI trial for 938 was started almost in parallel to the challenge trial. For 323 there is a greater than one year gap. So it is fair to infer 323 moved from a more backup candidate role to one that indeed merits progression to the next phase. But we knew that already from the latest company communications.
👍️ 9
DewDiligence DewDiligence 1 week ago
My bad—I retract the previous post. This 48-patient DDI trial won't cost much to run, so we shouldn't infer anything in particular from its starting. Apologies for jumping the gun.
👍️ 6
Fred Kadiddlehopper Fred Kadiddlehopper 1 week ago
Hi, Dew, could you please enlarge your comment here? I'm not sure what you are saying about it being a big deal and whether it was a voluntary decision. Thanks!
👍️0
DewDiligence DewDiligence 1 week ago
EDP-323 DDI study just listed yesterday… This is a pretty big deal, IMO. It seems unlikely that ENTA would initiate such a trial on its own volition.
👍️ 4
DewDiligence DewDiligence 1 week ago
CLDX CSU update:

https://www.globenewswire.com/news-release/2025/02/27/3034268/24180/en/Celldex-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Corporate-Update.html A global Phase 3 program in chronic spontaneous urticaria (CSU) consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) was initiated in July and enrollment is ongoing…. EMBARQ-CSU1 and EMBARQ-CSU2 will enroll approximately 915 patients each across 40 countries and 500 sites.

… “Our Phase 3 studies in CSU have been met with great enthusiasm from the global medical community and are actively enrolling patients around the world,” [said CLDX’s CEO]. Note: CLDX’s CSU compound (barzolvolimab) is an antibody, so it addresses a somewhat different market than ENTA’s EPS-1421.
👍️0
alertmeipp alertmeipp 1 week ago
It would be great but given we just had a large insider buy few weeks ago, seems a far stretch?

Happy to be wrong though
👍️0
go seek go seek 1 week ago
Perhaps we will get news of a RSV partnership soon… March 13.
👍️ 2
floblu14 floblu14 1 week ago
Thanks, Dewophile -

FYI -

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-positive-topline-results-edp
👍️ 1
dewophile dewophile 1 week ago
EDP-323

DDI study just listed yesterday

https://clinicaltrials.gov/study/NCT06847464?term=rsv%20enanta&aggFilters=status:rec&rank=3
👍️ 8
dewophile dewophile 2 weeks ago
I’m not worried about the opportunity in RSV. It’s akin to the flu so not like Covid where severity markedly decreased after an initial brutal wave bc it was a new virus
The peds market in RSV may never get an active vaccine after last years safety halt for MRNA and a moratorium on peds vaccine development. The adult market could get a bit smaller over time if ACIP loosens restrictions but that’s a longer way off now w RFK amd there will always be those who decline vaccination or have breakthrough despite vaccination
👍 6
willyw willyw 2 weeks ago
In the COVID run up I started buying more stock as I could tell the bar was low for Paxlovid.
And it seemed to me that they let the EUA run out before they had a chance to get a once a day, unboosted and more efficacious antiviral.
To be fair, after Delta, and after many had vaccinations or natural (albeit short term) immunity it was less of a 4 alarm fire.

But if a "delta" like strain re-emerged the world would find itself somewhat flatfooted and far less prepared than we should be.
So a layman like me wonders if it could have been handled better- but I'm in the cheap seats and have stayed mum.

In the same way I worried about the window of opportunity for Covid I'm now worried about the RSV window.
👍️ 1
vinmantoo vinmantoo 2 weeks ago
To be clear I am not buying into this conspiracy, I just wanted to clarify the argument for Vin.

Thanks dewophile. I see what the idea behind it was. I also don't buy it.
👍️0
dewophile dewophile 2 weeks ago
Got it. Makes sense that a lawyer would be conflicted out of certain cases (and then such an equivalent doesn’t in fact exist in pharma)
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
In the legal world there is often a mandatory waiting period before making the jump from one to the other, albeit it might be as short as 6 months in many cases.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
Often, it's not corruption, but the appearance of impropriety, that is enough to do harm to the reputations of the regulating agencies in question.
👍️ 1
dewophile dewophile 2 weeks ago
Not a great look but I kind of get it. You do your civil service but then want to make money and there are only so many options. You probably know lawyers that have moved between the public and private sector in a similar vein e.g. SEC lawyer now at a private firm defending companies , sometimes the very same ones that they may have been looking into for violations ? (I could be wrong here but guessing it happens in other sectors is my point)
👍️ 1
dewophile dewophile 2 weeks ago
I’m ok w allowing paxlovid to stay on the market without another trial in immune experienced people. I’m also okay with using immunological markers as surrogates for boosters in vaccines (this is not exclusive to Covid vaccines either). What I’m not okay with is making companies include symptoms like sense of smell that were less common since omicron. You already have a tougher population (vaccinated prior infected and also lower risk if running a pbo trial ), why not let companies narrow down to the most common symptoms (sore throat fever cough fatigue congestion ). Is a stat sign reduction in these symptoms a prior i not meaningful?! Such bs and I think the FDA sabotaged the ability to get better drugs to patients period.
I also don’t see why a noninferiority trial couldn’t be run although that would have to be large. But ENTA in so many words via email told me that the regulatory environment was the impediment to progressing 235 a long time ago and they were hoping the stance would change and looking to the Ensitrelvir data package and how FDA would handle that. In the meantime ensitrelvir was stat sig on the symptom score used in Asia, numerically better in the FDA score and stat sig in prevention and it’s still not available.
👍 6
mouton29 mouton29 2 weeks ago
At a lower level, I've read statistics that a majority of FDA reviewers end up at big pharma. Obviously not specifically PFE. But the point is, generally, it's not a great look.
👍️ 4
mouton29 mouton29 2 weeks ago
I doubt there was any explicit quid pro quo but the FDA and CDC have been pretty lenient with PFE in terms of approval and requiring randomized trials. E.g., notwithstanding the fact that the US government contracted to buy more than $10 billion of Paxlovid, the FDA didn't manage to require a randomized trial in the actual population that drug was being given to (vaxed, prior infection, ...) and let them abandon the EPIC-SR trial. Similarly, though not relevant to ENTA, they approved COVID vax boosters based solely on mouse data and have never required a randomized trial showing actual benefit.
👍 1 👍️ 2
DewDiligence DewDiligence 2 weeks ago
Ok—a singular case for an executive officer (rather than a non-employee director).
👍️0
mouton29 mouton29 2 weeks ago
PFE’s hiring Patricia Cavazzoni (former head of CDER) is not symptomatic of a “revolving door” policy or a quid pro quo regarding Pavlovid, but rather is a singular case, IMO.

Singular case? What about Scott Gottlieb?
👍️ 1
dewophile dewophile 2 weeks ago
To be clear I am not buying into this conspiracy, I just wanted to clarify the argument for Vin. It's not totally outlandish but I agree w you that CDER/FDA was impartial (yet misguided) visa vie ENTA and others in the space
👍️ 1
DewDiligence DewDiligence 2 weeks ago
PFE’s hiring Patricia Cavazzoni (former head of CDER) is not symptomatic of a “revolving door” policy or a quid pro quo regarding Pavlovid, but rather is a singular case, IMO.

Cavazzoni resigned two days prior to Trump’s inauguration, for reasons related to the new administration. That’s the entire story as far as I can tell.
👍️ 1
wags23 wags23 2 weeks ago
Bingo!!
👍️0
dewophile dewophile 2 weeks ago
“I made a comment about a serious conflict of interest regarding the CDER head that may have been a factor in the tanking of Enanta's stock.


Why in the world would it affect ENTA? “

Sounds like that poster may be checked out so I’ll take a stab. I think the suggestion is that CDER was in bed with PFE making the regulatory framework in Covid too challenging for new entrants to break in (thereby protecting paxlovid sales). Indeed the FDA insisted on using a Covid symptom score that may not have been optimal with the latest variants. Shionogi ran into this issue w ensitrelvir.
👍️ 1
vinmantoo vinmantoo 2 weeks ago
A British physician, Andrew Wakefield, published an article in Lancet around 25 years ago that postulated a link between the measles component of MMR and autism. He falsified the data and never disclosed that he received a huge sum from a lawyers group to find that link. The paper was eventually retracted and no link has ever been found between MMR and autism.

Yet Kennedy keeps lying that vaccines cause autism.

It is tragic that many children are being left unprotected against preventable diseases when there are safe and effective vaccines. Overwhelmingly, Americans have looked to the public health experts for information on vaccines and not to the Children's Health Fund or whatever RFK Jr organization is called. IMO, those public health experts bear the brunt of the responsibility for the current vaccine hesitancy that has led to decreased vaccination rates among children.

Kennedy keeps lying about vaccines. He among many others are the reason why vaccine skepticism is rising, to the detriment of the general population and individuals.

I made a comment about a serious conflict of interest regarding the CDER head that may have been a factor in the tanking of Enanta's stock.

Why in the world would it affect ENTA?

I post here infrequently and usually reluctantly. I thought the board may benefit form a different perspective regarding RFK Jr as I do believe there is a groupthink here that sometimes gets things very wrong. Going forward, I am not going to waste my time.

Post more often if you like. Nobody is saying you shouldn't. RFK Jr., is a proven liar and demagogue who has no business being head of HHS. Trying to look for some shred of positivity in that seems like a waste of time, but have at it. I will disagree when needed.

Neither you or Willy responded to that but instead ranted on about Greenland, planes falling out of the sky, Canadians booing our anthem. What a waste!

I am not ranting about Greenland, the guy in the White House is. I don't like planes falling out of the sky or people from our Northern neighbor and close ally Canada booing our national Anthem, but it is happening. It is indeed a waste.
👍️ 1
DewDiligence DewDiligence 2 weeks ago
I made a comment about a serious conflict of interest regarding the CDER head that may have been a factor in the tanking of Enanta's stock. Respectfully, I don’t think PFE’s hiring Patricia Cavazzoni (former head of CDER) had—or will have—any material effect on ENTA.
👍️ 3
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
There are some valid points in your position, like the corrupting revolving door between industry and the regulators, but RFKJr is simply the wrong standard bearer.
👍️ 4
radford radford 2 weeks ago
No it is not. A British physician, Andrew Wakefield, published an article in Lancet around 25 years ago that postulated a link between the measles component of MMR and autism. He falsified the data and never disclosed that he received a huge sum from a lawyers group to find that link. The paper was eventually retracted and no link has ever been found between MMR and autism.

It is tragic that many children are being left unprotected against preventable diseases when there are safe and effective vaccines. Overwhelmingly, Americans have looked to the public health experts for information on vaccines and not to the Children's Health Fund or whatever RFK Jr organization is called. IMO, those public health experts bear the brunt of the responsibility for the current vaccine hesitancy that has led to decreased vaccination rates among children.

This is not the place for that discussion, however, as it has little to do with Enanta.

I made a comment about a serious conflict of interest regarding the CDER head that may have been a factor in the tanking of Enanta's stock. Neither you or Willy responded to that but instead ranted on about Greenland, planes falling out of the sky, Canadians booing our anthem. What a waste!

I post here infrequently and usually reluctantly. I thought the board may benefit form a different perspective regarding RFK Jr as I do believe there is a groupthink here that sometimes gets things very wrong. Going forward, I am not going to waste my time.
👍️ 2 😂 1
vinmantoo vinmantoo 2 weeks ago
Is this also a victory for public health?

https://abcnews.go.com/Health/texas-measles-outbreak-grows-124-cases-unvaccinated/story?id=119158746
👍️0
willyw willyw 2 weeks ago
My *response* was to a post that may have also strayed a bit off topic.
also a huge win for public health in America.
Radford wrote about Kennedy's recent cabinet approval to HHS

I'm 100% in agreement with you about not using this board to massage facts or promote political agendas.
This may be a hard line to walk- considering the recent shutting down/shuttering of essential services (NIH/CDC/EPA)
👍️ 4
wags23 wags23 2 weeks ago
Your post is went way off topic.
👍️ 1

Your Recent History

Delayed Upgrade Clock